Skip to main content
TipRanks
Go Ultimate75% OFF

Apimeds Pharmaceuticals US, Inc. (APUS) Stock Statistics & Valuation Metrics

31 Followers

Total Valuation

Apimeds Pharmaceuticals US, Inc. has a market cap or net worth of $3.37M. The enterprise value is $10.20T.

Market Cap
$3.37M
Enterprise Value
$10.20T

Share Statistics

Apimeds Pharmaceuticals US, Inc. has 1,509,118 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
1,509,118
Owned by Insiders
―
Owned by Institutions
0.72%

Financial Efficiency

Apimeds Pharmaceuticals US, Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -7.39%.

Return on Equity (ROE)
-0.04
Return on Assets (ROA)
-0.04
Return on Invested Capital (ROIC)
-7.39%
Return on Capital Employed (ROCE)
-0.08
Revenue Per Employee
0
Profits Per Employee
-857.31K
Employee Count
7
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Apimeds Pharmaceuticals US, Inc. is -0.04. Apimeds Pharmaceuticals US, Inc.’s PEG ratio is 0.00.

PE Ratio
-0.04
PS Ratio
0.00
PB Ratio
0.03
Price to FCF
-0.22
Price to Operating Cash Flow
-0.24
PEG Ratio
0.00

Income Statement

In the last 12 months, Apimeds Pharmaceuticals US, Inc. had revenue of 0 and earned -6.00M in profits. Earnings per share was -5.50.

Revenue
0
Gross Profit
-5,706
Operating Income
-11.91M
Pretax Income
-6.00M
Net Income
-6.00M
EBITDA
-5.71M
Earnings Per Share (EPS)
-5.50

Cash Flow

In the last 12 months, operating cash flow was -13.86M and capital expenditures -53,369, giving a free cash flow of -13.92M billion.

Operating Cash Flow
-13.86M
Free Cash Flow
-13.92M
Free Cash Flow per Share
-8.52

Dividends & Yields

Apimeds Pharmaceuticals US, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-445.31%
Earnings Yield
-1720.19%

Stock Price Statistics

Beta
2.17
52-Week Price Change
-93.64%
50-Day Moving Average
3.44
200-Day Moving Average
9.94
Relative Strength Index (RSI)
34.67
Average Volume (3m)
3.75M

Financial Position

Apimeds Pharmaceuticals US, Inc. as a current ratio of 1.31, with Debt / Equity ratio of 5.06%

Current Ratio
1.31
Quick Ratio
1.31
Debt to Market Cap
0.43
Net Debt to EBITDA
-1.07
Interest Coverage Ratio
-42.09

Taxes

In the past 12 months, Apimeds Pharmaceuticals US, Inc. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Apimeds Pharmaceuticals US, Inc. EV to EBITDA ratio is -0.32, with an EV/FCF ratio of -1.25.

EV to Sales
0.00
EV to EBITDA
-0.32
EV to Free Cash Flow
-1.25
EV to Operating Cash Flow
-1.26

Balance Sheet

Apimeds Pharmaceuticals US, Inc. has $278.37K in cash and marketable securities with $14.58M in debt, giving a net cash position of -$14.30M billion.

Cash & Marketable Securities
$278.37K
Total Debt
$14.58M
Net Cash
-$14.30M
Net Cash Per Share
-$9.48
Tangible Book Value Per Share
$65.19

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Apimeds Pharmaceuticals US, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
0
Revenue Growth Forecast
―
EPS Growth Forecast
-1063.72%